Lowest-Rated StocksLowest-RatedNASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis $7.50 -0.40 (-5.06%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sage Therapeutics alerts: Email Address About Sage Therapeutics Stock (NASDAQ:SAGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sage Therapeutics alerts:Sign Up Key Stats Today's Range$7.45▼$8.0050-Day Range$7.35▼$13.0852-Week Range$7.19▼$28.26Volume1.16 million shsAverage Volume1.02 million shsMarket Capitalization$457.88 millionP/E RatioN/ADividend YieldN/APrice Target$16.06Consensus RatingReduce Company OverviewSage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Sage Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 88th PercentileSage Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 153rd out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingReduce Consensus RatingSage Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.95, and is based on 1 buy rating, 16 hold ratings, and 2 sell ratings.Amount of Analyst CoverageSage Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sage Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($6.47) to ($5.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sage Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.37% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 4.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.64 Percentage of Shares Shorted12.37% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 4.89%, indicating that investor sentiment is decreasing. News and Social Media2.3 / 5News Sentiment0.07 News SentimentSage Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Sage Therapeutics this week, compared to 6 articles on an average week.Search Interest2 people have searched for SAGE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sage Therapeutics' insider trading history. Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Stock News HeadlinesSAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead CaseSeptember 20 at 4:18 PM | globenewswire.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud LawsuitSeptember 20 at 2:27 PM | prnewswire.comForget Trump and KamalaForget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.September 20, 2024 | Investors Alley (Ad)Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)September 20 at 12:49 PM | globenewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) ShareholdersSeptember 20 at 5:45 AM | prnewswire.comLevi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGESeptember 19 at 1:28 PM | globenewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage TherapeuticsSeptember 19 at 10:09 AM | globenewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit - SAGESeptember 19 at 5:45 AM | prnewswire.comSee More Headlines SAGE Stock Analysis - Frequently Asked Questions How have SAGE shares performed this year? Sage Therapeutics' stock was trading at $21.67 at the beginning of the year. Since then, SAGE stock has decreased by 65.4% and is now trading at $7.50. View the best growth stocks for 2024 here. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.68) by $0.02. The company's revenue was up 249.8% on a year-over-year basis. Who are Sage Therapeutics' major shareholders? Sage Therapeutics' top institutional investors include Federated Hermes Inc. (1.11%), Renaissance Technologies LLC (0.92%), Dimensional Fund Advisors LP (0.85%) and Cubist Systematic Strategies LLC (0.80%). Insiders that own company stock include George Golumbeski and Elizabeth Barrett. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Netflix (NFLX). Company Calendar Last Earnings7/31/2024Today9/20/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees690Year FoundedN/APrice Target and Rating Average Stock Price Target$16.06 High Stock Price Target$25.00 Low Stock Price Target$8.00 Potential Upside/Downside+112.4%Consensus RatingReduce Rating Score (0-4)1.95 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($8.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-541,490,000.00 Net Margins-458.30% Pretax Margin-458.30% Return on Equity-55.87% Return on Assets-50.00% Debt Debt-to-Equity RatioN/A Current Ratio9.95 Quick Ratio9.95 Sales & Book Value Annual Sales$86.46 million Price / Sales5.34 Cash FlowN/A Price / Cash FlowN/A Book Value$13.32 per share Price / Book0.57Miscellaneous Outstanding Shares61,050,000Free Float56,872,000Market Cap$461.54 million OptionableOptionable Beta0.91 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:SAGE) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.